HC Wainwright Predicts Invivyd FY2029 Earnings

Invivyd, Inc. (NASDAQ:IVVD) – Equities researchers at HC Wainwright issued their FY2029 earnings estimates for Invivyd in a note issued to investors on Tuesday, February 4th. HC Wainwright analyst P. Trucchio anticipates that the company will earn $0.41 per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.57) per share.

A number of other equities analysts also recently commented on IVVD. Morgan Stanley reduced their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research report on Monday. Finally, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Invivyd has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Trading Down 6.2 %

IVVD opened at $1.98 on Wednesday. The company has a market capitalization of $236.85 million, a price-to-earnings ratio of -1.01 and a beta of 0.61. Invivyd has a 12-month low of $0.35 and a 12-month high of $5.10. The business’s fifty day simple moving average is $0.55 and its 200-day simple moving average is $0.83.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new position in shares of Invivyd during the 2nd quarter worth $421,000. Barclays PLC boosted its stake in Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after buying an additional 75,780 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares during the last quarter. State Street Corp raised its stake in shares of Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after acquiring an additional 35,904 shares during the period. Finally, Marshall Wace LLP raised its stake in shares of Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after acquiring an additional 31,992 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Insiders Place Their Bets

In other news, Director Terrance Mcguire sold 160,400 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the sale, the director now directly owns 4,202,679 shares in the company, valued at $2,479,580.61. This represents a 3.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders sold 816,466 shares of company stock worth $423,214. Corporate insiders own 17.90% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.